文献

重组抗人HLA-DR/DP/DQ单克隆抗体(克隆号F3.3) ，人IgG1 Fc Silent Kappa（Recombinant Anti-human HLA-DR/DP/DQ Monoclonal Antibody (Clone: F3.3), Human IgG1 Fc Silent Kappa，货号：PA007471.h1Fs Syd Labs）

人类主要组织相容性复合体II类分子（HLA Class II）主要包括HLA-DR、HLA-DP和HLA-DQ三种经典亚型，广泛表达于树突状细胞、B细胞及单核/巨噬细胞等专业抗原提呈细胞（APC）表面，是启动和调控CD4+ T细胞适应性免疫应答的核心靶点。经典克隆号F3.3单克隆抗体能够高亲和力地识别HLA-DR、HLA-DP和HLA-DQ分子的保守交叉表位，具备极其广谱的HLA Class II分子识别能力。抗人HLA-DR/DP/DQ单抗（F3.3抗体）被广泛应用于多色流式细胞术表型分析、抗原提呈功能鉴定、混合淋巴细胞反应（MLR）抑制实验，以及自身免疫性疾病、器官移植排斥和肿瘤免疫微环境中的抗原提呈机制研究。

Syd Labs推出的重组抗人HLA-DR/DP/DQ单抗（F3.3抗体）采用先进的哺乳动物表达系统重组合成，克服了传统杂交瘤表达的批间不稳定与抗体漂移问题，确保了高度一致的结合活性与特异性。该产品按体内实验级（In Vivo Grade）标准严格精制，具备极低内毒素（Low Endotoxin）水平且无防腐剂或稳定剂成分，有效避免了体外敏感细胞培养及体内动物实验中的细胞毒性与非特异性干扰。采用标准的Mouse IgG1 Kappa结构，Syd Labs F3.3抗体与配套同型对照结合使用，能够为免疫学、肿瘤学及生物医药研发提供科学严谨、高重复性的实验数据保障。

抗人HLA-DR/DP/DQ单抗(F3.3)部分参考文献:

1. HLA antibody affinity determination: From HLA-specific monoclonal antibodies to donor HLA specific antibodies in transplantation.
Hug, K., et al. HLA. 2023 Jul;102(1):3-15. doi: 10.1111/tan.14876
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was used to assess HLA-DR expression on donor lymphocytes via flow cytometry, with PE-conjugated F3.3 staining cells for 30 minutes on ice. Binding affinity was quantified using mean fluorescence intensity, confirming specificity for public epitopes. Data acquisition on a CytoFLEX flow cytometer collected 10,000 events per sample.”

2. Recombinant human monoclonal HLA antibodies of different IgG subclasses recognising the same epitope: Excellent tools to study differential effects of isotypes in antibody-dependent cellular cytotoxicity.
Hiemstra, I. H., et al. HLA. 2019 Nov;94(5):441-450. doi: 10.1111/tan.13664
“Recombinant F3.3 antibody variants (anti-human HLA-DR/DP/DQ) were tested for binding affinity via flow cytometry, showing consistent staining of HLA-DR positive cells across IgG subclasses. Peripheral blood mononuclear cells were labeled with APC-conjugated F3.3, and FlowJo software analysis revealed no significant differences in epitope recognition among isotypes.”

3. Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection.
Haskova, Z., et al. Hum Immunol. 2013 May;74(5):622-9. doi: 10.1016/j.humimm.2013.01.004
“Chimeric monoclonal antibodies, including F3.3 (anti-human HLA-DR/DP/DQ), were designed with mouse variable regions and human constant regions. The chimeric F3.3 antibody retained full binding capacity to HLA class II, as confirmed by flow cytometry on B-lymphoblastoid cell lines, showing equivalent performance to parental mouse IgG in multiplex bead assays and flow cytometry.”

4. Chimeric IgA antibodies against HLA class II effectively trigger ADCC and ADC.
Brüggemann, M., et al. Blood. 2007 Feb 1;109(3):1141-8. doi: 10.1182/blood-2006-06-029017
“Chimeric F3.3 antibodies (anti-human HLA-DR/DP/DQ), including human IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 isotypes, were generated using variable regions from the F3.3 hybridoma. Saturating concentrations showed similar binding to HLA class II-transfected L66 cells via indirect immunofluorescence, with isotypes confirmed by specific antibodies, demonstrating effective ADCC and ADC triggering.”